The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
21
The identification of AF38469: an orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin.EBI
H. Lundbeck
1
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.EBI
Durham University
21
In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.EBI
Medical University of South Carolina
6
Lysosomal Degradation of Extracellular Targets: Innovations and Implications.EBI
Usona Institute
1
The signal peptide as a new target for drug design.EBI
University of Nevada
20
The identification of novel acid isostere based inhibitors of the VPS10P family sorting receptor Sortilin.EBI
Aarhus University
5
Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicineBDB
Shanghai Medicilon
129
ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOFBDB
University of North Carolina at Chapel Hill
96
SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOFBDB
Accutar Biotechnology
19
BRANCHED MACROCYCLIC 4-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1BDB
Janssen Pharmaceutica
3
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.BDB
Pfizer
22
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.BDB
Glaxosmithkline